{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053948","form_type":"8-K","ticker":null,"cik":"0001805890","company_name":"Fusion Pharmaceuticals Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.221199+00:00","generated_at":"2026-06-02T19:39:27.597929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fusion Q1 net loss $33.7M; AstraZeneca acquisition on track for Q2 2024","bullets":["Net loss of $33.7M ($0.40/sh) vs $24.3M ($0.45/sh) in Q1 2023; R&D spend $21.3M.","Cash and investments $283.1M as of March 31, 2024; expected to fund operations into Q4 2025.","Definitive agreement to be acquired by AstraZeneca for up to $2.4B ($21/sh cash + $3 CVR); HSR clearance and Canadian Competition Bureau no-action received; expected close Q2 2024.","Interim data for FPI-2265 in mCRPC presented at AACR 2024; Phase 2 dose optimization trial to start Q2 2024, Phase 3 registrational trial planned for 2025.","FPI-1434 Phase 1 trial shows encouraging early findings; no DLTs in 25 kBq/kg cohort; stable disease and anti-tumor activity observed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053948","json":"https://secwatch.observer/filing/0000950170-24-053948.json","markdown":"https://secwatch.observer/filing/0000950170-24-053948.md","text":"https://secwatch.observer/filing/0000950170-24-053948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/0000950170-24-053948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/fusn-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:39:27.597929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"069c017850b85fc83acecbc00a23a030afbe1eee","claim":"Fusion Pharmaceuticals Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Fusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/0000950170-24-053948-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}